NICE says yes to BI's Vargatef
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has confirmed its turnaround on Boehringer Ingelheim's Vargatef (nintedanib) for treating National Health Service patients with lung cancer. Final and binding guidance published today confirms that the drug can be used in combination with docetaxel, and in line with its EU marketing authorization, for patients with non-small cell lung cancer of adenocarcinoma histology. BI managed to convince NICE to reverse its initial no by offering a confidential discount on the drug's list price.